MX2022002324A - Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos. - Google Patents

Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.

Info

Publication number
MX2022002324A
MX2022002324A MX2022002324A MX2022002324A MX2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A MX 2022002324 A MX2022002324 A MX 2022002324A
Authority
MX
Mexico
Prior art keywords
hybridoma
developing
platform
efficient
therapeutic antibody
Prior art date
Application number
MX2022002324A
Other languages
English (en)
Inventor
Dhaya Seshasayee
Meredith Carroll Hazen
Zhonghua Lin
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2022002324A publication Critical patent/MX2022002324A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/166—Animal cells resulting from interspecies fusion
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente tecnología generalmente se refiere a los procedimientos mejorados para producir anticuerpos, colecciones de anticuerpos, hibridomas, colecciones de hibridomas, etc. Por ejemplo, estos procedimientos incrementan la cantidad de linfocitos B específicos al antígeno producidos, incrementan la cantidad de hibridomas y/o incrementan la cantidad de anticuerpos monoclonales que se pueden producir en un ciclo de producción dado.
MX2022002324A 2019-08-30 2020-08-28 Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos. MX2022002324A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962894660P 2019-08-30 2019-08-30
PCT/US2020/048440 WO2021041834A1 (en) 2019-08-30 2020-08-28 Developing an efficient hybridoma platform for therapeutic antibody discovery

Publications (1)

Publication Number Publication Date
MX2022002324A true MX2022002324A (es) 2022-04-06

Family

ID=74686058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002324A MX2022002324A (es) 2019-08-30 2020-08-28 Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.

Country Status (13)

Country Link
US (1) US20220177551A1 (es)
EP (1) EP4021489A4 (es)
JP (1) JP2022546412A (es)
KR (1) KR20220053596A (es)
CN (1) CN114340660A (es)
AR (1) AR119866A1 (es)
AU (1) AU2020336473A1 (es)
BR (1) BR112022003170A2 (es)
CA (1) CA3148521A1 (es)
IL (1) IL290937A (es)
MX (1) MX2022002324A (es)
TW (1) TW202122107A (es)
WO (1) WO2021041834A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117098839A (zh) * 2021-02-05 2023-11-21 美国安进公司 非终末抗体发现方法和单细胞测定

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945857B2 (en) * 2005-07-01 2015-02-03 John Schrader Methods of isolating cells and generating monoclonal antibodies
WO2007124755A1 (en) * 2006-05-02 2007-11-08 The Antibody Project Aps Method for immunizing an avian species
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
US9938356B2 (en) * 2014-11-10 2018-04-10 Medimmune Limited Binding molecules specific for CD73 and uses thereof

Also Published As

Publication number Publication date
US20220177551A1 (en) 2022-06-09
BR112022003170A2 (pt) 2022-05-17
AR119866A1 (es) 2022-01-19
CA3148521A1 (en) 2021-03-04
KR20220053596A (ko) 2022-04-29
EP4021489A1 (en) 2022-07-06
EP4021489A4 (en) 2023-10-11
CN114340660A (zh) 2022-04-12
JP2022546412A (ja) 2022-11-04
AU2020336473A1 (en) 2022-03-03
IL290937A (en) 2022-04-01
WO2021041834A1 (en) 2021-03-04
TW202122107A (zh) 2021-06-16

Similar Documents

Publication Publication Date Title
NZ728874A (en) Anti-pd-1 monoclonal antibody and obtaining method therefor
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
MX344595B (es) Humanizacion rapida de anticuerpos.
JP2015028021A5 (es)
NZ592036A (en) Methods for producing antibodies from plasma cells
MX2017008541A (es) Anticuerpos biespecificos contra calicreina y factor xii del plasma.
WO2012092376A3 (en) Comprehensive monoclonal antibody generation
PH12019501089A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
AU2017428934A8 (en) Dynamic human antibody light chain libraries
MX2022002324A (es) Desarrollo de una plataforma de hibridomas eficiente para el descubrimiento de anticuerpos terapeuticos.
ZA202203622B (en) Anti-cd47 monoclonal antibody and use thereof
MX2021012767A (es) Metodos para tratar el cancer de prostata con un anticuerpo anti-psma/cd3.
WO2011159959A3 (en) Methods and systems for generating, validating and using monoclonal antibodies
MX2021012765A (es) Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3.
MX2022003833A (es) Anticuerpos anti-kir3dl3 y sus usos.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
ATE370163T1 (de) Antikörper zur isolierung und/oder identifizierung mesenchymaler stammzellen und verfahren zur isolierung und/oder identifizierung mesenchymaler stammzellen
WO2019070435A8 (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
ZA202208337B (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
WO2012104014A8 (en) A method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human c44-fragment of agrin
EA202091053A1 (ru) Модифицированные c- и ch1-домены
MY190116A (en) Antibody composition and method for producing the same